Literature DB >> 31463628

Impact of fracture characteristics and disease-specific complications on health-related quality of life in osteogenesis imperfecta.

Masaki Matsushita1, Kenichi Mishima2, Satoshi Yamashita3, Nobuhiko Haga4, Sayaka Fujiwara4, Keiichi Ozono5, Takuo Kubota5, Taichi Kitaoka5, Naoki Ishiguro2, Hiroshi Kitoh2,6.   

Abstract

Osteogenesis imperfecta (OI) is a connective tissue disease with bone fragility. Several studies have indicated that physical function in adult OI was correlated to the disease severity, but there have been no reports delineating the impact of the fracture characteristics and disease-specific complications on health-related quality of life (HRQoL). The purpose of this study is to clarify the factors impacted on HRQoL in adult OI patients. We conducted a cross-sectional study between July 2016 and March 2018 and sent a questionnaire regarding HRQoL using Short Form-36 (SF-36) to the OI patients at the age of 20 years or older who had a medical history of the investigators' institutions. The 40 patients completely answered the SF-36. Mental component summary and role/social component summary were unremarkable. Physical component summary (PCS) was significantly associated with z-score for height, teeth abnormality, and cardiopulmonary insufficiency (partial regression coefficient, 3.04, - 9.70, and - 11.35; p, < 0.001, 0.047, and 0.025, respectively). PCS was also significantly lower in the patients who had an initial fracture before the age of 2 years than those without occurrence of fractures until 2 years old (25.80 ± 17.15 versus 44.20 ± 16.54; p = 0.002), or those who had lower extremity fractures more than five times as compared with normal populations. Physical function was decreased in OI patients who had fractures before 2 years old, especially in lower extremity. Appropriate medical managements for cardiopulmonary insufficiency are required not only to maintain physical function but also to decrease mortality.

Entities:  

Keywords:  Cardiopulmonary insufficiency; Fracture; Osteogenesis imperfecta; Quality of life; SF-36

Mesh:

Year:  2019        PMID: 31463628     DOI: 10.1007/s00774-019-01033-9

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  42 in total

1.  Causes of death in osteogenesis imperfecta.

Authors:  S J McAllion; C R Paterson
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

2.  Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.

Authors:  Anne D Letocha; Holly L Cintas; James F Troendle; James C Reynolds; Christopher E Cann; Edith J Chernoff; Suvimol C Hill; Lynn H Gerber; Joan C Marini
Journal:  J Bone Miner Res       Date:  2005-01-18       Impact factor: 6.741

3.  Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult.

Authors:  Fergus E McKiernan
Journal:  Osteoporos Int       Date:  2005-05-19       Impact factor: 4.507

Review 4.  Valvular and aortic diseases in osteogenesis imperfecta.

Authors:  Arvin Lamanna; Trevor Fayers; Sophie Clarke; William Parsonage
Journal:  Heart Lung Circ       Date:  2013-06-21       Impact factor: 2.975

5.  Osteogenesis imperfecta: a genetic, radiological, and epidemiological study.

Authors:  P E Andersen; M Hauge
Journal:  Clin Genet       Date:  1989-10       Impact factor: 4.438

6.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

7.  Cardiovascular involvement in osteogenesis imperfecta.

Authors:  J Hortop; P Tsipouras; J A Hanley; B J Maron; J R Shapiro
Journal:  Circulation       Date:  1986-01       Impact factor: 29.690

8.  Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.

Authors:  Ralph Sakkers; Dieke Kok; Raoul Engelbert; Alice van Dongen; Maarten Jansen; Hans Pruijs; Ab Verbout; Dave Schweitzer; Cuno Uiterwaal
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

9.  Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study.

Authors:  Mahim Jain; Allison Tam; V Reid Sutton; Sandesh C S Nagamani; Jay R Shapiro; Robert D Steiner; Peter A Smith; Michael B Bober; Tracy Hart; David Cuthbertson; Jeff Krischer; Mary Mullins; Sunil Bellur; Peter H Byers; Melanie Pepin; Michaela Durigova; Francis H Glorieux; Frank Rauch; Brendan Lee
Journal:  Genet Med       Date:  2018-07-04       Impact factor: 8.822

10.  Initial report of the osteogenesis imperfecta adult natural history initiative.

Authors:  Laura L Tosi; Matthew E Oetgen; Marianne K Floor; Mary Beth Huber; Ann M Kennelly; Robert J McCarter; Melanie F Rak; Barbara J Simmonds; Melissa D Simpson; Carole A Tucker; Fergus E McKiernan
Journal:  Orphanet J Rare Dis       Date:  2015-11-14       Impact factor: 4.123

View more
  4 in total

1.  Hospital admissions of patients with osteogenesis imperfecta in the English NHS.

Authors:  S Kolovos; M K Javaid; R Pinedo-Villanueva
Journal:  Osteoporos Int       Date:  2021-01-07       Impact factor: 4.507

2.  Health-related Quality of Life in Adult Patients with Multiple Epiphyseal Dysplasia and Spondyloepiphyseal Dysplasia.

Authors:  Masaki Matsushita; Kenichi Mishima; Yasunari Kamiya; Nobuhiko Haga; Sayaka Fujiwara; Keiichi Ozono; Takuo Kubota; Taichi Kitaoka; Shiro Imagama; Hiroshi Kitoh
Journal:  Prog Rehabil Med       Date:  2021-12-07

3.  Chronic pain in adults with osteogenesis imperfecta and its relationship to appraisal, coping, and quality of life: A cross-sectional study.

Authors:  Rubén Muñoz Cortés; José Francisco Soriano Pastor; Vicente Monsalve Dolz
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

4.  Role of Fzd6 in Regulating the Osteogenic Differentiation of Adipose-derived Stem Cells in Osteoporotic Mice.

Authors:  Tianli Wu; Zhihao Yao; Gang Tao; Fangzhi Lou; Hui Tang; Yujin Gao; Xiaojuan Yang; Jingang Xiao
Journal:  Stem Cell Rev Rep       Date:  2021-05-26       Impact factor: 5.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.